Go Pro

PROCEPT BioRobotics (PRCT) Competitors

PROCEPT BioRobotics logo
$20.41 0.00 (0.00%)
Closing price 08/7/2026 04:00 PM Eastern
Extended Trading
$20.32 -0.09 (-0.47%)
As of 08/7/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

PRCT vs. ITGR, HAE, IRTC, ESTA, and TMDX

Should you buy PROCEPT BioRobotics stock or one of its competitors? MarketBeat compares PROCEPT BioRobotics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PROCEPT BioRobotics include Integer (ITGR), Haemonetics (HAE), iRhythm Technologies (IRTC), Establishment Labs (ESTA), and TransMedics Group (TMDX). These companies are all part of the "healthcare equipment" industry.

How does PROCEPT BioRobotics compare to Integer?

PROCEPT BioRobotics (NASDAQ:PRCT) and Integer (NYSE:ITGR) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

Integer has a net margin of 6.97% compared to PROCEPT BioRobotics' net margin of -32.53%. Integer's return on equity of 12.79% beat PROCEPT BioRobotics' return on equity.

Company Net Margins Return on Equity Return on Assets
PROCEPT BioRobotics-32.53% -30.62% -22.10%
Integer 6.97%12.79%6.48%

PROCEPT BioRobotics has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market. Comparatively, Integer has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market.

PROCEPT BioRobotics presently has a consensus target price of $28.00, indicating a potential upside of 37.19%. Integer has a consensus target price of $109.86, indicating a potential downside of 12.16%. Given PROCEPT BioRobotics' stronger consensus rating and higher probable upside, equities research analysts plainly believe PROCEPT BioRobotics is more favorable than Integer.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PROCEPT BioRobotics
2 Sell rating(s)
10 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.19
Integer
0 Sell rating(s)
13 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.07

89.5% of PROCEPT BioRobotics shares are held by institutional investors. Comparatively, 99.3% of Integer shares are held by institutional investors. 4.0% of PROCEPT BioRobotics shares are held by insiders. Comparatively, 1.1% of Integer shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Integer has higher revenue and earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PROCEPT BioRobotics$308.05M3.77-$95.57M-$1.94N/A
Integer$1.85B2.29$102.81M$3.6634.17

In the previous week, PROCEPT BioRobotics had 21 more articles in the media than Integer. MarketBeat recorded 53 mentions for PROCEPT BioRobotics and 32 mentions for Integer. Integer's average media sentiment score of 0.72 beat PROCEPT BioRobotics' score of 0.02 indicating that Integer is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
PROCEPT BioRobotics
4 Very Positive mention(s)
1 Positive mention(s)
44 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Integer
17 Very Positive mention(s)
1 Positive mention(s)
8 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Integer beats PROCEPT BioRobotics on 9 of the 17 factors compared between the two stocks.

How does PROCEPT BioRobotics compare to Haemonetics?

Haemonetics (NYSE:HAE) and PROCEPT BioRobotics (NASDAQ:PRCT) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, profitability and media sentiment.

Haemonetics has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market. Comparatively, PROCEPT BioRobotics has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market.

In the previous week, PROCEPT BioRobotics had 22 more articles in the media than Haemonetics. MarketBeat recorded 53 mentions for PROCEPT BioRobotics and 31 mentions for Haemonetics. Haemonetics' average media sentiment score of 0.71 beat PROCEPT BioRobotics' score of 0.02 indicating that Haemonetics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Haemonetics
7 Very Positive mention(s)
4 Positive mention(s)
14 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
PROCEPT BioRobotics
4 Very Positive mention(s)
1 Positive mention(s)
44 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

99.7% of Haemonetics shares are held by institutional investors. Comparatively, 89.5% of PROCEPT BioRobotics shares are held by institutional investors. 2.1% of Haemonetics shares are held by insiders. Comparatively, 4.0% of PROCEPT BioRobotics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Haemonetics has higher revenue and earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Haemonetics$1.35B2.94$97.31M$2.0442.89
PROCEPT BioRobotics$308.05M3.77-$95.57M-$1.94N/A

Haemonetics has a net margin of 7.12% compared to PROCEPT BioRobotics' net margin of -32.53%. Haemonetics' return on equity of 27.55% beat PROCEPT BioRobotics' return on equity.

Company Net Margins Return on Equity Return on Assets
Haemonetics7.12% 27.55% 9.65%
PROCEPT BioRobotics -32.53%-30.62%-22.10%

Haemonetics currently has a consensus price target of $90.89, suggesting a potential upside of 3.87%. PROCEPT BioRobotics has a consensus price target of $28.00, suggesting a potential upside of 37.19%. Given PROCEPT BioRobotics' higher possible upside, analysts clearly believe PROCEPT BioRobotics is more favorable than Haemonetics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Haemonetics
0 Sell rating(s)
4 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.73
PROCEPT BioRobotics
2 Sell rating(s)
10 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.19

Summary

Haemonetics beats PROCEPT BioRobotics on 11 of the 16 factors compared between the two stocks.

How does PROCEPT BioRobotics compare to iRhythm Technologies?

iRhythm Technologies (NASDAQ:IRTC) and PROCEPT BioRobotics (NASDAQ:PRCT) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.

iRhythm Technologies has higher revenue and earnings than PROCEPT BioRobotics. iRhythm Technologies is trading at a lower price-to-earnings ratio than PROCEPT BioRobotics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
iRhythm Technologies$747.14M5.64-$44.55M-$0.43N/A
PROCEPT BioRobotics$308.05M3.77-$95.57M-$1.94N/A

In the previous week, PROCEPT BioRobotics had 27 more articles in the media than iRhythm Technologies. MarketBeat recorded 53 mentions for PROCEPT BioRobotics and 26 mentions for iRhythm Technologies. iRhythm Technologies' average media sentiment score of 0.59 beat PROCEPT BioRobotics' score of 0.02 indicating that iRhythm Technologies is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
iRhythm Technologies
9 Very Positive mention(s)
4 Positive mention(s)
8 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive
PROCEPT BioRobotics
4 Very Positive mention(s)
1 Positive mention(s)
44 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

iRhythm Technologies presently has a consensus price target of $179.36, indicating a potential upside of 40.30%. PROCEPT BioRobotics has a consensus price target of $28.00, indicating a potential upside of 37.19%. Given iRhythm Technologies' stronger consensus rating and higher probable upside, analysts clearly believe iRhythm Technologies is more favorable than PROCEPT BioRobotics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
iRhythm Technologies
1 Sell rating(s)
1 Hold rating(s)
12 Buy rating(s)
2 Strong Buy rating(s)
2.94
PROCEPT BioRobotics
2 Sell rating(s)
10 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.19

iRhythm Technologies has a net margin of -1.69% compared to PROCEPT BioRobotics' net margin of -32.53%. iRhythm Technologies' return on equity of 10.11% beat PROCEPT BioRobotics' return on equity.

Company Net Margins Return on Equity Return on Assets
iRhythm Technologies-1.69% 10.11% 1.53%
PROCEPT BioRobotics -32.53%-30.62%-22.10%

89.5% of PROCEPT BioRobotics shares are held by institutional investors. 1.0% of iRhythm Technologies shares are held by company insiders. Comparatively, 4.0% of PROCEPT BioRobotics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

iRhythm Technologies has a beta of 1.3, meaning that its share price is 30% more volatile than the broader market. Comparatively, PROCEPT BioRobotics has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market.

Summary

iRhythm Technologies beats PROCEPT BioRobotics on 13 of the 17 factors compared between the two stocks.

How does PROCEPT BioRobotics compare to Establishment Labs?

PROCEPT BioRobotics (NASDAQ:PRCT) and Establishment Labs (NASDAQ:ESTA) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk and dividends.

Establishment Labs has a net margin of -15.82% compared to PROCEPT BioRobotics' net margin of -32.53%. PROCEPT BioRobotics' return on equity of -30.62% beat Establishment Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
PROCEPT BioRobotics-32.53% -30.62% -22.10%
Establishment Labs -15.82%-205.79%-10.75%

89.5% of PROCEPT BioRobotics shares are owned by institutional investors. Comparatively, 72.9% of Establishment Labs shares are owned by institutional investors. 4.0% of PROCEPT BioRobotics shares are owned by insiders. Comparatively, 10.0% of Establishment Labs shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, PROCEPT BioRobotics had 35 more articles in the media than Establishment Labs. MarketBeat recorded 53 mentions for PROCEPT BioRobotics and 18 mentions for Establishment Labs. Establishment Labs' average media sentiment score of 0.24 beat PROCEPT BioRobotics' score of 0.02 indicating that Establishment Labs is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
PROCEPT BioRobotics
4 Very Positive mention(s)
1 Positive mention(s)
44 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Establishment Labs
3 Very Positive mention(s)
3 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

PROCEPT BioRobotics has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market. Comparatively, Establishment Labs has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market.

Establishment Labs has lower revenue, but higher earnings than PROCEPT BioRobotics. Establishment Labs is trading at a lower price-to-earnings ratio than PROCEPT BioRobotics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PROCEPT BioRobotics$308.05M3.77-$95.57M-$1.94N/A
Establishment Labs$211.08M10.79-$51.06M-$1.31N/A

PROCEPT BioRobotics currently has a consensus price target of $28.00, suggesting a potential upside of 37.19%. Establishment Labs has a consensus price target of $100.25, suggesting a potential upside of 29.49%. Given PROCEPT BioRobotics' higher possible upside, research analysts clearly believe PROCEPT BioRobotics is more favorable than Establishment Labs.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PROCEPT BioRobotics
2 Sell rating(s)
10 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.19
Establishment Labs
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.67

Summary

Establishment Labs beats PROCEPT BioRobotics on 10 of the 17 factors compared between the two stocks.

How does PROCEPT BioRobotics compare to TransMedics Group?

PROCEPT BioRobotics (NASDAQ:PRCT) and TransMedics Group (NASDAQ:TMDX) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability.

PROCEPT BioRobotics has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market. Comparatively, TransMedics Group has a beta of 1.9, suggesting that its stock price is 90% more volatile than the broader market.

TransMedics Group has higher revenue and earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PROCEPT BioRobotics$308.05M3.77-$95.57M-$1.94N/A
TransMedics Group$605.49M4.79$190.29M$3.8921.57

TransMedics Group has a net margin of 22.69% compared to PROCEPT BioRobotics' net margin of -32.53%. TransMedics Group's return on equity of 15.88% beat PROCEPT BioRobotics' return on equity.

Company Net Margins Return on Equity Return on Assets
PROCEPT BioRobotics-32.53% -30.62% -22.10%
TransMedics Group 22.69%15.88%5.95%

PROCEPT BioRobotics presently has a consensus price target of $28.00, indicating a potential upside of 37.19%. TransMedics Group has a consensus price target of $124.18, indicating a potential upside of 48.03%. Given TransMedics Group's stronger consensus rating and higher possible upside, analysts clearly believe TransMedics Group is more favorable than PROCEPT BioRobotics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PROCEPT BioRobotics
2 Sell rating(s)
10 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.19
TransMedics Group
1 Sell rating(s)
6 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.38

In the previous week, PROCEPT BioRobotics had 24 more articles in the media than TransMedics Group. MarketBeat recorded 53 mentions for PROCEPT BioRobotics and 29 mentions for TransMedics Group. TransMedics Group's average media sentiment score of 0.03 beat PROCEPT BioRobotics' score of 0.02 indicating that TransMedics Group is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
PROCEPT BioRobotics
4 Very Positive mention(s)
1 Positive mention(s)
44 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
TransMedics Group
6 Very Positive mention(s)
2 Positive mention(s)
10 Neutral mention(s)
6 Negative mention(s)
0 Very Negative mention(s)
Neutral

89.5% of PROCEPT BioRobotics shares are held by institutional investors. Comparatively, 99.7% of TransMedics Group shares are held by institutional investors. 4.0% of PROCEPT BioRobotics shares are held by company insiders. Comparatively, 6.9% of TransMedics Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

TransMedics Group beats PROCEPT BioRobotics on 15 of the 17 factors compared between the two stocks.

Get PROCEPT BioRobotics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PRCT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PRCT vs. The Competition

MetricPROCEPT BioRoboticsHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.16B$5.76B$7.00B$12.99B
Dividend YieldN/A1.78%2.58%10.20%
P/E Ratio-10.5224.26270.5925.05
Price / Sales3.7768.36599.4584.15
Price / CashN/A33.5528.8937.44
Price / Book3.126.1111.216.43
Net Income-$95.57M$149.01M$3.45B$348.10M
7 Day Performance11.04%2.54%3.41%2.68%
1 Month Performance-2.30%0.78%-0.71%-0.83%
1 Year Performance-46.86%4.93%77.31%23.97%

PROCEPT BioRobotics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PRCT
PROCEPT BioRobotics
2.7636 of 5 stars
$20.41
flat
$28.00
+37.2%
-46.9%$1.16B$308.05MN/A430
ITGR
Integer
2.3816 of 5 stars
$124.45
+2.7%
$103.71
-16.7%
+17.5%$4.12B$1.85B31.0311,000
HAE
Haemonetics
2.7273 of 5 stars
$86.79
+1.5%
$78.89
-9.1%
+62.4%$3.89B$1.33B42.963,009
IRTC
iRhythm Technologies
4.2061 of 5 stars
$124.66
+6.4%
$184.71
+48.2%
-19.3%$3.85B$747.14MN/A2,400
ESTA
Establishment Labs
3.2899 of 5 stars
$92.80
+0.3%
$93.75
+1.0%
+122.5%$2.72B$211.08MN/A1,004

Related Companies and Tools


This page (NASDAQ:PRCT) was last updated on 8/10/2026 by MarketBeat.com Staff.
From Our Partners